Petrelintide / CT-388
A fixed dose combination (FDC) of amylin + GLP-1/GIP for those needing additional benefits beyond amylin monotherapy
The petrelintide/CT-388 fixed-dose combination is suitable for once-weekly subcutaneous administration.
Zealand Pharma and Roche aim to maximize the dose of petrelintide and optimize the dose of CT-388, with the objective of maximizing weight loss efficacy whilst optimizing the weight loss experience. The petrelintide/CT-388 FDC will target the specific segments of people with overweight and obesity who need additional benefits beyond amylin monotherapy, including greater weight loss efficacy and/or enhanced glycemic control.
aZealand Pharma has a collaboration and license agreement with Roche for petrelintide, including co-development and co-commercialization in the U.S. and Europe.
- PROGRAM Petrelintide / CT-388
-
PARTNERS
- Phase 1
Development status
In the first half of 2026, Zealand Pharma and Roche expect to initiate a Phase 2 trial with petrelintide/CT-388.
A global collaboration & license agreement
In March 2025, Zealand Pharma and Roche entered a global collaboration and license agreement to co-develop and co-commercialize petrelintide and combination products with petrelintide, including a fixed-dose combination product of petrelintide and CT-388, Roche’s lead incretin asset and potential best-in-class GLP-1/GIP receptor dual agonist. This collaboration reflects our shared vision to develop petrelintide as a future foundational therapy for weight management and related comorbidities, redefining the standard of care for people with overweight and obesity by establishing the leading amylin-based franchise.
Obesity
More about the disease area
Overweight and obesity are associated with more than 220 complications and comorbidities, including cardiovascular disease, liver disease, type 2 diabetes, kidney disease, and neuroinflammation.
